Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
Authors' conclusion
Long-term projections based on the SURPASS-2 trial results indicate that 5, 10 and 15 mg doses of tirzepatide are likely to be cost-effective versus semaglutide 1.0 mg for the treatment of type 2 diabetes in the United States.
Study context
- Population
- Simulated T2D cohort with baseline characteristics from the 40-week SURPASS-2 trial; US
- Comparison
- Tirzepatide 5, 10 and 15 mg vs semaglutide 1.0 mg
- Outcome
- Incremental cost-effectiveness ratio vs semaglutide (US$ per QALY gained)
- Follow-up
- 50-year time horizon
Methodological detailsmodelling study, PRIME Type 2 Diabetes Model, 50-year time horizon, US healthcare payer perspective, based on SURPASS-2 trial, 3% annual discounting, Insulin intensification when HbA1c reached 7.5%, Direct costs in 2021 US$; costs and utilities from published sources
- Modelling study
- PRIME Type 2 Diabetes Model
- 50-year time horizon
- US healthcare payer perspective
- Based on SURPASS-2 trial
- 3% annual discounting
- Insulin intensification when HbA1c reached 7.5%
- Direct costs in 2021 US$; costs and utilities from published sources
Main finding
As reported in the abstract
Further findings
- Tirzepatide remained cost-effective vs semaglutide over a range of sensitivity analyses
Original publication
Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes Obes Metab. Published 20 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →